<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002036</url>
  </required_header>
  <id_info>
    <org_study_id>060A</org_study_id>
    <secondary_id>0001-008</secondary_id>
    <nct_id>NCT00002036</nct_id>
  </id_info>
  <brief_title>Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)</brief_title>
  <official_title>Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV&#xD;
      human serum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HIV Immune Serum Globulin (Human)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Proof of HIV infection.&#xD;
&#xD;
          -  Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no&#xD;
             zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or &gt; 3 months&#xD;
             of AZT therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  HIV-induced neurological disease.&#xD;
&#xD;
          -  IgA negative.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active substance abuse.&#xD;
&#xD;
          -  Use of immunomodulating drugs such as steroids or interferons.&#xD;
&#xD;
          -  HIV-induced neurological disease.&#xD;
&#xD;
          -  IgA negative.&#xD;
&#xD;
        Required with a diagnosis of AIDS:&#xD;
&#xD;
          -  = or &gt; 3 months of zidovudine (AZT) therapy.&#xD;
&#xD;
        Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Immunization, Passive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Sera</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

